CTLA4 and diffuse large B-cell lymphoma: Another area of interest for a prospective clinical trial to treat DLBCL is to combine pembrolizumab, a PD-1 inhibitor, with ipilimumab, an antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4).